This review examines the underlying causes associated with ED and PE and evaluates currently available treatment options and those under investigation.
The first data from radiologic analyses in the phase 3 clinical trial of golimumab (Simponi, Centocor Ortho Biotech) for treatment of active psoriatic arthritis demonstrate the benefit of this new anti-TNF-alpha agent for inhibiting joint damage.
This review examines the underlying causes associated with ED and PE and evaluates currently available treatment options and those under investigation.
Roflumilast is a novel, orally active phosphodiesterase 4 inhibitor currently under review by FDA for the treatment of patients with moderate-to-severe COPD.
New formulation: Diclofenac sodium topical solution (Pennsaid) was approved on November 5, 2009, to treat the signs and symptoms of osteoarthritis of the knee.
New molecular entity: Pralatrexate injection (Folotyn) was approved on September 24, 2009, for the treatment of patients with relapsed or refractory peripheral T-cell lymphoma.
Clinical Pharmacology
Practice Tools
